0001821586 2026-08-10 2026-08-10 0001821586 1 2026-08-10 2026-08-10 0001821586 2 2026-08-10 2026-08-10 0001821586 3 2026-08-10 2026-08-10 0001821586 4 2026-08-10 2026-08-10 0001821586 5 2026-08-10 2026-08-10 0001821586 6 2026-08-10 2026-08-10 0001821586 1 2026-08-10 2026-08-10 0001821586 2 2026-08-10 2026-08-10 iso4217:USD pure S-3 S-3ASR EX-FILING FEES 0001821586 MoonLake Immunotherapeutics N/A true false S-3 MoonLake Immunotherapeutics false Equity Ordinary shares, $0.0001 par value per share true 0.0001381 false Equity Preference shares, $0.0001 par value per share true 0.0001381 false Debt Debt Securities true 0.0001381 false Other Warrants true 0.0001381 false Other Units true 0.0001381 false Equity Ordinary shares, $0.0001 par value per share true 300000000.00 0.0001381 41430.00 300000000.00 41430.00 0.00 41430.00 0.00 The amount to be registered consists of an indeterminate number of ordinary shares, preference shares, debt securities, warrants and/or units. There is also being registered hereunder such currently indeterminate number of (i) ordinary shares or other securities of the registrant as may be issued upon conversion of, or in exchange for, convertible or exchangeable preference shares and/or debt securities registered hereby, or (ii) ordinary shares, preference shares, debt securities or units as may be issued upon exercise of warrants registered hereby, as the case may be. Any securities registered hereunder may be sold separately or as units with the other securities registered hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. The proposed maximum per security and aggregate offering prices per class of securities will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and are not specified as to each class of security. Separate consideration may or may not be received for securities that are issuable on exercise, conversion, or exchange of other securities, or that are issued in units. See Note 1. See Note 1. See Note 1. See Note 1. In accordance with Rules 456(b) and 457(r) under the Securities Act, the registrant is deferring payment of the filing fees relating to the securities that are registered and available for sale under this registration statement, other than the fees in connection with the $300,000,000 of the registrant's ordinary shares that may be issued and sold from time to time under the Sales Agreement, dated August 31, 2023, with Leerink Partners LLC, as sales agent, as amended by Amendment No. 1 to the Sales Agreement, dated August 10, 2026. true MoonLake Immunotherapeutics S-3 333-274286 2023-08-31 41430.00 Unallocated (Universal) Shelf 300000000.00 true MoonLake Immunotherapeutics S-3 333-274286 2023-08-31 41430.00 The offering that includes the Unsold Securities (as defined below) under the August 2023 Registration Statement (as defined below) is hereby terminated. The registrant has previously registered the offer and sale of up to $1,000,000,000 of securities pursuant to a registration statement on Form S-3 (File No. 333-274286), which was initially filed with the Securities and Exchange Commission on August 31, 2023 and became effective on September 11, 2023 (the "August 2023 Registration Statement"). In connection with the filing of the August 2023 Registration Statement, the registrant made a contemporaneous fee payment in the amount of $110,200.00. Of the $1,000,000,000 of securities registered under the August 2023 Registration Statement, $558,820,982 of securities remains unsold (the "Unsold Securities"). Pursuant to Rule 457(p) under the Securities Act, the registration fee of $41,430.00 that has already been paid and remains unused with respect to the Unsold Securities is hereby offset against the registration fee of $41,430.00 due for this offering. The offering that includes the Unsold Securities under the August 2023 Registration Statement is hereby terminated. The registrant has previously registered the offer and sale of up to $1,000,000,000 of securities pursuant to the August 2023 Registration Statement. In connection with the filing of the August 2023 Registration Statement, the registrant made a contemporaneous fee payment in the amount of $110,200.00. Of the $1,000,000,000 of securities registered under the August 2023 Registration Statement, $558,820,982 of securities remains unsold. Pursuant to Rule 457(p) under the Securities Act, the registration fee of $41,430.00 that has already been paid and remains unused with respect to the Unsold Securities is hereby offset against the registration fee of $41,430.00 due for this offering. The offering that includes the Unsold Securities under the August 2023 Registration Statement is hereby terminated.